Kidney PATIENT Act of 2023

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 10545, American Relief Act, 2025; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 10545, American Relief Act, 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027; Request for Information to CMS on "Medicare $2 Drug list Model" (Executive Order 14087 of October 14, 2022); H.R.5074/S.5410, the Kidney PATIENT Act; H.R.4104/S.1976, the Preserving Patient Access to Home Infusion Act; H.R.10545, the American Relief Act, 2025;

Client expense: $412,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

Issues related to the Medicare Secondary Payer Act, including HR 6860 and S. 5018, Restore Protections for Dialysis Patients Act; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act, H.R. 5074/S. 4510; issues related to home dialysis.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes S. 4510 - The Kidney Patient Act Issues related to patient access to infection prevention.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) final rule

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) final rule

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024, issues related to CY 2025 CMS final rule for ESRD PPS and Quality Improvement Program.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024, issues related to CY 2025 CMS final rule for ESRD PPS and Quality Improvement Program.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Living Donor Protection Act (H.R. 2923 / S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027/S.4469) Honor Our Living Donors Act (H.R. 6020) Medigap Expansion Act Restore Protections for Dialysis Patients Act (H.R. 6860, S.5081) Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day" (H.Res.1124) Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 (H.R. 5074, S. 4510) PASTEUR Act (H.R. 2940/S. 1355) Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2023 The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323) The CARING for Social Determinants Act of 2023 (H.R. 1066) End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.6860/ S. 5018 Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, Kidney Patient Act of 2023 H.R. 8594 - Restore Protections for Dialysis Patients Act, all provisions S. 4750 - Restore Protections for Dialysis Patients Act, all provisions H.R.5027 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2023

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074, the Kidney Patient Act S 4510, the Kidney Patient Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074/S 4510, The Kidney Patient Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease, Acute Kidney Injury, Dialysis, ESRD Treatment Choice Model. Telehealth. ESRD PPS Quality Incentive Program. Issues related to access for rural and underserved patients with ESRD. Kidney Patent Access to Technologically Innovative and Essential Nephrology Treatments. H.R. 5074 - Kidney PATIENT Act of 2023. H.R. 10545 - American Relief Act. Calendar Year 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule (CMS-1805-P).

Client expense: Not reported · Firm income: $70,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Issues related to Medicare ESRD benefit and chronic kidney disease management. H.R.5074/S.4510 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023; S.4510, A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to reimbursement for treatment of End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S.5018, Restore Protections for Dialysis Patients Act H.R. 5074/S.4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to access to treatment for End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S.5018, Restore Protections for Dialysis Patients Act H.R. 5074/S.4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to access to treatment for End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act Issues related to reimbursement for treatment of End Stage Renal Disease (ESRD)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 8075, Improving Access to Home Dialysis Act. S. 2407, H.R. 4818, the "Treat and Reduce Obesity Act" S. 1832, H.R. 3842, "Expanding Access to Diabetes Self-Management Training Act" H.R. 5074, S. 4510 "Kidney PATIENT Act of 2023" H.R. 6860, S. 5018 "Restore Protections for Dialysis Patients Act." H.R. 7856, S. 4094, "PREVENT Diabetes Act." Inflation Reduction Act Medicare drug pricing, including Medicare Part D Redesign Program Guidance. Support for Medicare Part D Protected Classes coverage. Kidney patient health and management under Medicare Advantage. Medicare activities and coverage for COVID-19 patients. Protect Medicaid eligibility. Activities regarding implementation of HHS Advancing American Kidney Health Initiative. Activities to address rural health access and quality. Comments on Medicare $2 Drug List Model RFI.

Client expense: $95,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to Centers for Medicare and Medicaid Innovation (CMMI) models; Medicare concurrent hospice and dialysis; Issues relating to staffing and workforce; Issues related to Medicare reimbursement; Kidney PATIENT Act (H.R. 5074/S. 4510); Home dialysis policies.

Client expense: Not reported · Firm income: $90,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to Centers for Medicare and Medicaid Innovation (CMMI) models; Medicare concurrent hospice and dialysis; Issues relating to staffing and workforce; Issues related to Medicare reimbursement; Home dialysis policies; Kidney Patient Act (H.R. 5074/S. 4510).

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Client expense: $670,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Client expense: $670,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 (H.R. 5074).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 (H.R. 5074).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 (H.R. 5074).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 (H.R. 5074).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 (H.R. 5074).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 (H.R. 5074).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

FY 25 Congressional appropriations: -Increase funding for Health Resources and Services Administration (HRSA) Organ Transplantation Program -Increase NIH funds, including proportional increase for NIDDK to support kidney research -Provide $25 million to KidneyX to continue development of an artificial kidney and other innovations innovative kidney therapeutics and technologies -Support CDC Chronic Kidney Disease Initiative -Increase funding Veterans Health Administration Kidney Health Program -Address the implementation of the retrospective trend adjustment in the CKCC model Legislation: Explore the establishment of an Officer of Kidney Health and Transplantation at HHS Support implementation of the Securing the U.S. Organ Procurement and Transplantation Act (H.R. 2544/S. 1668), including clarifying HRSA's ability to use OPTN patient waitlist registration fees Increase support for living donors including through the Honor Our Living Donors Act, The Living Organ Donor Tax Credit Act (H.R. 6171), and the Living Donor Protection Act (H.R. 2923/S. 1384) Increase patient choice by passing the Kidney PATIENT Act (H.R. 5074), the Restore Protections for Dialysis Patients Act (H.R. 6860), the Chronic Kidney Disease Research and Treatment Act, (H.R. 5027/S. 4469), and the Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674) Bolster the kidney health care workforce, including by passing the Healthcare Workforce Resilience Act (H.R. 6205/S. 3211), the Strengthening Medicare for Patients and Providers Act (HR 2474), The Specialty Physicians Advancing Rural Care Act (S. 705/ H.R. 2761), and the Resident Physician Shortage Act (HR 2389/S. 1302) Regulatory: Increase kidney health coordination, innovation, and reimbursement through ESRD PPS/QIP, PFS, and ESRD-QIP Measure Set Review Improve transparency and accountability in transplant system to maximize access to kidney transplant, including through the HRSA OPTN Modernization Initiative Establish a federal screening recommendation for kidney diseases

Client expense: $90,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074 Kidney PATIENT Act of 2023; Kidney PATIENT Act of 2024 Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074, the Kidney Patient Act S 4510, the Kidney Patient Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)

Client expense: $280,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes S. 4510 - The Kidney Patient Act Issues related to patient access to infection prevention.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) proposed rule

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5067/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074/S.4510, Kidney Patient Act; issues related to CY 2025 End-Stage Renal Disease (ESRD) Proposed Payment Systems (PPS) proposed rule

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE